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The extracellular matrix (ECM) exists as a dynamic network of biophysical and
biochemical factors that maintain tissue homeostasis. Given its sensitivity to
changes in the intra- and extracellular space, the plasticity of the ECM can
be pathological in driving disease through aberrant matrix remodelling. In
particular, cancer uses the matrix for its proliferation, angiogenesis, cellular
reprogramming and metastatic spread. An emerging field of matrix biology
focuses on proteoglycans that regulate autophagy, an intracellular process
that plays both critical and contextual roles in cancer. Here, we review the
most prominent autophagic modulators from the matrix and the current
understanding of the cellular pathways and signalling cascades that mechanistically drive their autophagic function. We then critically assess how their
autophagic functions influence tumorigenesis, emphasizing the complexities
and stage-dependent nature of this relationship in cancer. We highlight
novel emerging data on immunoglobulin-containing and proline-rich receptor-1, heparanase and thrombospondin 1 in autophagy and cancer. Finally,
we further discuss the pro- and anti-autophagic modulators originating from
the ECM, as well as how these proteoglycans and other matrix constituents
specifically influence cancer progression.

1. Introduction
The extracellular matrix (ECM) has long been understood as the dynamic macromolecular network that contributes both biophysical and biochemical factors to
regulate tissue homeostasis. Through continuous remodelling, the ECM changes
its composition, elasticity and structure to influence a wide array of biological
functions, including adhesion, proliferation, wound healing, differentiation,
migration and angiogenesis [1–4]. The ECM also has a profound impact on intracellular signalling as it oversees the storage and release of growth factors such as
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor β (TGFβ) and many others
[5–7]. Given the extraordinary responsiveness of the ECM to physiological
changes in the tissue, these processes that are intrinsic to the ECM allowing it
to play a critical role in physiological settings can also be dysregulated in disease
pathology [8].
In fibrosis and cancer, aberrant matrix remodelling and abnormal ECM deposition alter the makeup, rigidity and stiffness of the matrix [1,9,10]. Many cell
types in the ECM, including fibroblasts, epithelial cells, immune cells and endothelial cells, deposit extracellular molecules and contribute to the elasticity and
turnover of the matrix. Of these, fibroblasts are the predominant cells that
synthesize and maintain the bulk of these ECM molecules that control the overall
structure and mechanical properties of the matrix. For example, fibroblasts
secrete elastin, collagens, glycosaminoglycans and glycoproteins, and can also
© 2022 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
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The autophagic machinery functions as a counterpoint to cell
growth and anabolic events activated when growth is not
possible or is suppressed [22]. Therefore, there is an intrinsic
antagonism between autophagy and growth. Macroautophagy (herein referred to as autophagy) is an intracellular
process by which damaged or unused proteins, lipids and
organelles in the cytoplasm undergo catalysis via the autophagosome-lysosomal pathway [23]. It involves approximately
20 autophagy-related (ATG) proteins that initiate and perpetuate autophagy, starting from the pre-autophagosomal
structure (PAS) maturing into a double-membrane, spherical
autophagosome to the final step of lysosomal fusion [24–26].
Self-digestion through this conserved pathway allows for the
recycling of nucleotides, fatty acids, amino acids and sugars
to maintain intracellular homeostasis [23,27]. Although the
precise influence of autophagy on carcinogenesis has been
widely debated, autophagy is generally understood to inhibit
tumour growth and invasion in the early stages of tumour
growth while promoting tumour invasion and metastasis in
later stages of tumorigenesis.
In the early stages, autophagy inhibits mutagenesis, chronic
inflammation and tissue injury, processes that collectively foster
tumorigenesis [28–30]. For instance, enhanced autophagy
blocks Human Epidermal Growth Factor 2 (HER2)-driven

3. Pro-autophagic signalling
An emerging field of research that was overlooked for many
years is based on the discovery that a soluble proteoglycan
named decorin is capable of inducing autophagic flux in endothelial cells of various histogenetic backgrounds [40] (figure 1).
After this original discovery made nearly 10 years ago, other
proteoglycans and bioactive fragments have emerged as
pro- or anti-autophagic molecules [41–43]. One example is
endorepellin, the C-terminal domain V of the large multidomain heparan sulfate proteoglycan (HSPG) perlecan
[44–46], which is liberated from the endothelial basement
membrane as a bioactive, processed species [47–49]. Originally,
perlecan was isolated from renal basement membranes [50] but
was later discovered to be a constituent of the colon carcinoma
cell surface [51] and was eventually found in nearly all cells and
tissues, both vascular and avascular [52,53]. Perlecan was soon
identified as a major driver of angiogenesis via binding to
angiogenic growth factors such as FGF2 and using antisense
approaches in various systems [54–56].
Signalling through its 3 laminin-like globular (LG1-3)
domains [57], endorepellin exerts pro-autophagic and
angiostatic effects on vascular endothelia [58–60] by using a
complex dual receptor antagonism, whereby concurrently interacts with VEGF receptor 2 (VEGFR2) and α2β1 integrin [61], two
transmembrane receptors that are uniquely co-expressed in vascular endothelial cells [62–64]. Through its LG1/2 domains
binding to the VEGFR2 immunoglobulin (Ig) 3–5 ectodomain
motifs [65,66], endorepellin signals as partial agonist to activate
autophagic machinery and suppress angiogenesis downstream
[67–70]. Specifically, endorepellin activates VEGFR2 signalling,
leading to downstream phosphorylation and activation of adenosine monophosphate (AMP)-activated protein kinase
(AMPK) at Thr172 on its α subunit. This results in the canonical inhibition of mTOR [67], upregulation of autophagy
proteins Peg3, LC3-II, Beclin 1 and p62 and formation of autophagosomes containing LC3, Peg3, p62, Beclin 1, Vps34 and
mTOR [67,68]. Recently, we also discovered that endorepellinevoked autophagy results in catabolic degradation of hyaluronan synthase 2 (HAS2), leading to a significant reduction in
extracellular hyaluronan (HA) and angiogenic inhibition
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2. Effect of autophagy on tumour
progression

mammary tumorigenesis suggesting that therapies directed at
increasing autophagic flux may become an appropriate therapeutic strategy for HER2-positive mammary breast cancers
[31]. Autophagy also suppresses tumorigenic build-up of p62
[32] and deletion of critical autophagy genes Atg7 and
Becn1, resulting in malignancy in mice [33–35]. By contrast,
later stages of oncogenesis are supported by autophagic activation, in which autophagy promotes tumour invasion and
spread, growth, survival and chemotherapy resistance. It does
this via maintaining tumour cell viability and homeostasis,
conferring cytoprotection against metabolic stress and nutrient
deprivation, DNA damage and hypoxia [28,30,36–39]. More
recently, a developing and evolving body of work investigates
the autophagic regulatory cues that originate from proteoglycans in the ECM. These autophagic modulators, both
pro- and anti-autophagic in nature, are now being explored
within the realm of the tumour microenvironment. Their implications on oncogenesis are critical in understanding the impact
of the ECM on tumour progression, especially in the context of
tumour vascularization.

royalsocietypublishing.org/journal/rsob

differentiate into myofibroblasts under the influence of TGFβ
and elevated tensile stress. Myofibroblast differentiation can
then lead to increased deposition of fibrillar collagens and
fibronectin, resulting in fibrotic changes and aberrant wound
healing [11]. Fibroblasts also drive matrix proteolysis via
matrix metalloproteinases (MMPs) and ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)
family proteases [12,13].
In cancer, solid tumours manipulate the ECM to establish
and maintain a tumour-supportive milieu via secreting
matrix components and enzymes that change the makeup of
their microenvironment [14]. One common effect of matrix
remodelling in the tumour milieu is desmoplasia, the increased
deposition of fibrillar collagen and cross-linkage causing
elevated tissue rigidity and stiffness [10]. Another oncological
process perpetuated by the matrix is epithelial–mesenchymal
transition (EMT), the process by which epithelial cell-derived
carcinomas lose their tight cell–cell contacts, change morphology and motility, and metastasize from the tumour mass
[15]. Multiple matrix molecules oversee EMT, including TGFβ
[10]. Concurrently, cancer cells modify the activity of stromal
cells to potentiate oncogenesis through matrix remodelling.
Incited by biophysical changes in the ECM stiffness such
as desmoplasia and continual paracrine exposure to neighbouring cancer cells, resident fibroblasts within a solid
tumour differentiate into cancer-associated fibroblasts (CAFs)
[16,16,17]. CAFs, in turn, recruit endothelial and immune
cells to the tumour via secreting a variety of chemokines and
growth factors including VEGFA (vascular endothelial
growth factor A), PDGF ( platelet-derived growth factor) and
HGF (hepatocyte growth factor). Overall, activation of CAFs
is integral in tumour vascularization, progression and chemoresistance [18–20], leading to unfavourable prognoses and
clinical outcomes [21].
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Figure 1. Schematic depiction of various pro-autophagic ECM components, their respective receptors and downstream signalling events. Please consult the text for
additional information. The graphic was created with BioRender.com.
[69,70]. Notably, interfering with HA metabolism suppresses
glioma cell proliferation by regulating autophagy [71].
In cancer, endorepellin demonstrates promising anti-oncogenic potential by inhibiting tumour growth, neovascularization
and metabolism in squamous carcinoma and Lewis lung
carcinoma [3,72]. Interestingly, endorepellin has also shown
promise as a biomarker as systemic levels of its LG3 domain
were elevated in vivo in pancreatic and breast cancer as
well as a variety of other diseases including chronic renal
nephropathy, IgA nephropathy, premature rupture of fetal
membranes, Down syndrome and refractory cytopenia with
multilineage dysplasia [73–83].
Another bioactive proteoglycan fragment, endostatin, is
the N-terminal domain of the HSPG collagen XVIII and
exerts pro-autophagic and anti-angiogenic effects in the
vascular endothelial basement membrane [84]. Signalling
through α5β1 integrin, endostatin activates autophagy in
vascular endothelia [85] while concurrently inhibiting cell
migration [86]. Like endorepellin, endostatin also induces
autophagic degradation of HAS2, which would also inhibit
HA-induced angiogenesis downstream [69,70]. In the context
of cancer, endostatin also exhibits anti-cancer properties
by therapeutically suppressing tumour vascularization in
breast cancer and malignant keratinocytes [87]. Of note,
Endostar, a novel recombinant human endostatin, effectively
induces autophagy in human hepatocellular carcinoma cells,
resulting in a marked suppression of tumour growth and
increased cell death [88]. Furthermore, treatment of Endostar
in murine lung carcinoma also suppressed tumour vascularization while concurrently activating autophagic machinery
through the PI3 K/AKT/mTOR pathway [89].

Decorin, a small leucine-rich proteoglycan [57], is another
well-studied molecule with a vast interacting network [90,91]
and broad biological activities in various organs and specialized
tissues including bone [92], tendon/ligaments [93–97], teeth
and skin, among others. Soluble decorin acts as a monomer in
solution [98] and binds to several receptor tyrosine kinase
(RTK), including epidermal growth factor (EGFR) [99–101],
Met [102] and insulin growth factor receptor-1 (IGFR-1)
[103,104], thereby inducing autophagy via outside-in cues
from the ECM [105]. Like endorepellin, decorin binds to
VEGFR2, leading to phosphorylation of AMPK and upregulation and recruitment of LC3, Beclin 1 and Peg3 to the
autophagosome [40,106–108]. Consequently, endothelial
VEGFA is profoundly degraded downstream of decorinevoked autophagy [109,110], while secretion of the angiostatic
molecule thrombospondin-1 is upregulated extracellularly
[111,112]. In the cancer milieu, decorin signals through EGFR
and Met receptors found on the surface of cancer cells,
effectively resulting in decreased HIF-1α and marked angiostasis of the tumour vasculature, suppression of tumour growth
and enhanced mitophagy [99,102,110,110,113,114]. In response
to fasting in vivo, decorin is also critical in overseeing the
metabolic changes in the hexosamine biosynthetic pathway
and modulations in cardiac function [115]. Notably, these
initial observations of decorin-evoked autophagic flux have
been recently confirmed in other systems including intervertebral disc cells [116], trophoblasts [117] and glioma cells [118]. Our
recent discovery that decorin deficiency promotes EMT and
colon cancer metastasis [119] is supported by the observations
that exogenous decorin inhibits EMT in glioma cells [118] as
well as inflammatory breast cancer growth and metastasis [120].
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4. IGPR-1, a novel bridge between cell
adhesion and autophagy
There is mounting evidence for a cooperative exchange
between cell adhesion and autophagy. Specifically, the autophagic flux can regulate adhesion dynamics to mediate neurite
outgrowth and synaptic plasticity [141]. Immunoglobulincontaining and proline-rich receptor-1 (IGPR-1), also known
as transmembrane and immunoglobulin domain containing 2
(TMIGD2), is a novel cell adhesion molecule expressed
on the surfaces of epithelial and endothelial cells that has
become a promising matrix protein of interest due to its
unique role at the endothelial-cancer cell interface [142,143].
Although its signalling is not triggered by matrix-residing
molecules, IGPR-1 receives extracellular signalling through
cell–cell interactions, which propagates intracellular signalling
cascades that modulate both autophagy and tumour angiogenesis (figure 2). In endothelial cells, IGPR-1 is localized
in adherens junctions and undergoes trans-homophilic
dimerization to maintain endothelial cell–cell adhesion and
barrier function. Of note, the trans-homophilic dimerization
of IGPR-1 between adjacent endothelial cells results in its
phosphorylation at serine 220. This phosphorylation is necessary for its role in regulating cell–cell adhesion [144]. Like
endorepellin and endostatin, IGPR-1 inhibits cell migration
via regulating actin polymerization and focal adhesions yet
induces capillary tube formation and angiogenesis via
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ovarian granulosa cells, VEGFA induces autophagy through
the AKT/PI3 K pathway such that siRNA knockdown of
VEGFA inhibits autophagy and attenuates AKT phosphorylation, whereas VEGFA overexpression promotes autophagy
and increases AKT phosphorylation [138]. In turn, autophagy
also regulates VEGFA levels downstream, where VEGFA itself
is an autophagic substrate in endothelial cells such that inhibiting autophagy results in an accumulation of intracellular
VEGFA and activating autophagy depletes VEGFA levels
[109]. Further, autophagic deficiency via atg7 deletion in uterine stromal cells results in elevated VEGFA and increased
vascular permeability [139].
VEGFA plays a key role in promoting tumour angiogenesis and is targeted in many anti-angiogenic therapies [137].
However, the specific functions of VEGFA-evoked autophagy
in regulating cancer progression have yet to be investigated
in depth. Of note, one study of ovarian cancer demonstrates
that autophagy induced downstream of VEGFA promotes
chemotherapy resistance, such that suppressing VEGFA
expression inhibits autophagy biomarkers, increases apoptosis and decreases chemotherapeutic resistance overall [140].
Further investigation into the role of VEGFA on autophagy
and cancer pathology would benefit this growing field of
matrix-derived autophagic effectors in the context of cancer.
Although the molecular mechanism of several of the
above-mentioned pro-autophagic inducers is not yet completely elucidated, the overwhelming majority of these
extracellular ‘outside-in’ pro-autophagic cues [105] occur in
the absence of nutrient deprivation and are thus considered
non-canonical routes of autophagy induction. As the field of
pro-autophagic ECM proteins in cancer expands, the breadth
of understanding and utilization of these non-canonical forms
of autophagic activation in treating cancer will also evolve.

royalsocietypublishing.org/journal/rsob

Another small leucine-rich proteoglycan, biglycan induces
autophagosome formation in both macrophages and cardiomyocytes via signalling through the TLR4–CD44 receptor
complex and TLR4 alone, respectively. In renal ischemia/reperfusion injury (IRI), biglycan not only recruits M1 macrophages
to the site of renal IRI, but it also increases autophagy within
these macrophages, effectively curtailing kidney inflammation
and tubular damage at the renal ischemic site [121]. Indeed,
biglycan is involved in a hepatorenal cross-talk, that is, biglycan
produced by the cirrhotic liver could be a circulating messenger
for renal pathophysiology via triggering inflammation and
autophagy, ultimately affecting disease outcome [122]. In cardiomyocytes, biglycan confers cytoprotective mechanisms from
IRI-induced tissue damage while modulating autophagy
[123]. However, unlike decorin, endorepellin, endostatin and
biglycan foster tumour angiogenesis in metastatic cancer via
upregulating VEGFA levels and VEGFA–VEGFR2 signalling
[124,125]. Tumour endothelia further exploit these pro-angiogenic effects by epigenetically activating BGN expression via
hypomethylation of its promoter [126,127]. These pro-autophagic effects of biglycan have yet to be explored in the extracellular
milieu of cancer. Thus, future investigations on the role of
biglycan in modulating autophagy in tumour-associated
macrophages and its effects on tumour angiogenesis would
provide invaluable information on matrix-derived autophagic
stimuli in cancer inflammatory response.
Collagen VI is an ECM protein secreted by fibroblasts in a
wide variety of tissues that is deposited as a microfibrillar
network in the matrix through a series of complex biosynthetic
steps and filamentous assembly. In addition to maintaining
biomechanical integrity, collagen VI offers cytoprotective
roles in a broad spectrum of cell types, including chondrocytes,
neurons, fibroblasts, cardiomyocytes and myofibres [128]. For
instance, collagen VI inhibits spontaneous apoptosis and
oxidative stress in central nervous system neurons [129]. Collagen VI is also essential in regulating autophagic flux, a
critical component to establishing its cytoprotective functions
[130]. In skeletal muscle, collagen VI-evoked autophagic flux
in myocytes prevents myofibre degeneration due to collagen
VI muscular dystrophies [131] or muscle wasting due to physical exercise [132]. Interestingly, activating autophagy via
spermidine or pterostilbene both reduced muscle defects and
myopathy in collagen VI-deficient mice [133,134].
In cancer, collagen VI promotes tumour angiogenesis
and inflammation via the recruitment of endothelial cells and
macrophages. Endotrophin, the C5 fragment of the α3 chain
of collagen VI, functions as a chemoattractant for endothelial
cell recruitment, thus inducing angiogenesis in the tumour
microenvironment [135]. Finally, collagen VI further aids
tumour progression by inducing EMT and promoting
chemotherapy resistance [136]. While its pro-tumorigenic
functions have not been investigated in the context of its proautophagic capabilities, this unexplored area of study would
be highly anticipated as the role of ECM-derived autophagic
regulators in cancer progression has been demonstrated in a
number of matrix proteins.
VEGFA is a dimeric glycoprotein involved heavily in
angiogenesis through the regulation of endothelial cell proliferation, survival and migration, as well as vascular permeability.
A well-studied angiogenic factor in the matrix, VEGFA, is upregulated in hypoxic conditions via signalling through VEGFR2
[137]. Not only paramount in overseeing the angiogenesis,
VEGFA also is itself a regulator of autophagy. In bovine
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binding SH3 protein interacting with Nck (SPIN90/WISH) in
endothelial cells [142] (figure 2).
In the tumour microenvironment, IGPR-1 expressed on
the cell surface of endothelia binds HHLA2, expressed not
only on the tumour cells but also on tumour-associated
macrophages. These paracrine signalling interactions aid
tumour progression, resulting in immunosuppressed
tumour milieu and angiogenic stimulation [145,146]. Further,
colon cancer cells also upregulate IGPR-1 expression to
enhance tumour cell–cell interaction, or ‘multicellular aggregation’, in order to optimize survival and protect against
chemotherapeutic agents [147]. Recently, it was shown that
NEDD4 ubiquitin E3 ligase binds to IGPR-1 and mediates
its polyubiquitination leading to lysosomal degradation
[148], suggesting that inhibitors of the lysosomal pathway
could enhance IGPR-1 levels. Notably, both nutrient deprivation and amino acid starvation induce IGPR-1 activation
through Ser220 phosphorylation. In turn, activated IGPR-1
induces phosphorylating activation of AMPK, thus stimulating
canonical autophagic machinery downstream, including
Unc-51-like kinase 1 (ULK1), Beclin 1, and lipidated microtubule-associated protein light chain 3 (LC3-II) [149] (figure 2).
Collectively, these observations bridge the gap between cell
adhesion and autophagy, positing IGPR-1 as a novel proautophagic and pro-angiogenic cell surface receptor at the
endothelial-cancer cell interface.

5. Anti-autophagic signalling
One of the largest matrix proteins with a protein core of
approximately 470 kDa, perlecan is an important HSPG
deposited extracellularly in basement membranes, cartilage,
bone marrow and muscle [150,151]. Perlecan regulates a
broad spectrum of biological processes, not limited to angiogenesis [152–158], autophagy [151,159], endocytosis [160],
cell adhesion [161,162], thrombosis [163], blood-brain barrier
integrity [164] and lipid catabolism [165,166]. By contrast
with its pro-autophagic C-terminal domain V endorepellin,
perlecan as a whole inhibits autophagy via mTOR complex
1 (mTORC1) activation (figure 3). Mice lacking perlecan
expression through Hspg2 deletion showed increased autophagy due to inadequate mTORC1 activation in their
slow-twitch soleus muscles, as demonstrated by elevated
levels of autophagic markers LC3-II and phosphorylated
AMPK alongside decreased phosphorylation of p70S6 K, a
downstream target of mTORC1 [167].
As part of its pro-angiogenic mechanism of action, perlecan
binds growth factors through its heparan sulfate chains and presents them to their cognate receptors [168,169]. These growth
factors include a number of angiokines such as VEGFA,
PDGF, FGFs 2, 7 and 18 and progranulin [46,170–173]. In line
with its ability to bind and facilitate growth factor signalling,
perlecan in the tumour matrix promotes tumour angiogenesis,
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growth and invasion [55,157,172,174,175]. Further, its
expression is significantly elevated in metastatic melanoma
and other cancer cell lines [51,153,176,177]. CAFs in pancreatic
cancer also secrete high levels of perlecan into the tumour
microenvironment to aid in metastasis [178].
Yet another small leucine-rich proteoglycan, lumican, regulates a host of physiological and disease processes, including
fibrocyte differentiation [179], wound healing [180,181], glucose
homeostasis [182], inflammation [183,184], cell migration [185],
cancer [186–188] and angiogenesis [189]. In cancer, lumican
responds in a tissue-specific manner, both inhibiting cancer
proliferation in melanoma [190,191] and pancreatic [192,193],
breast [194–196] and prostate cancers [197] while inducing
growth and metastasis in lung [198] and gastric cancers
[199,200]. In pancreatic ductal adenocarcinoma (PDAC) following surgical resection, high levels of lumican are correlated
with decreased recurrence and prolonged patient survival,
implicating lumican as an anti-oncogenic agent in this
tissue-specific context. Further, lumican signals as an EGFR
antagonist in PDAC, thereby blocking Akt signalling and HIF1α activity downstream and suppressing glycolysis and
proliferation [192,193]. Importantly, lumican inhibits autophagy
in PDAC via downregulating AMPK activity (figure 3).
Therefore, since autophagy confers resistance against the
chemotherapeutic agent gemcitabine in PDAC, extracellular
lumican effectively sensitizes cancer cells to chemotherapy
treatment via autophagic inhibition [201].
Laminin α2 is a subunit of heterotrimeric laminin 211, a
prominent laminin isoform found in the basement membranes of skeletal muscle, Schwann cells and astrocytes and
pericytes of brain capillaries [202]. Laminins function as scaffold proteins attaching the cell surface to the ECM. For
instance, the carboxyl end of laminin α2 binds to the dystrophin-associated glycoprotein complex, whereas the amino
end binds both α1β1 and α2β1 integrins [203]. Dysfunctional
laminin α2 caused by mutations within the LAMA2 gene
encoding laminin α2 results in LAMA2-related muscular

dystrophies (MDC1A), the most common subtype of congenital muscular dystrophy [204]. Laminin α2 itself is an
autophagy inhibitor, as autophagy genes and proteins are
upregulated in laminin α2-deficient muscle in an MDC1A
mouse model (figure 3). Notably, systemic pharmacological
inhibition of autophagy reduced muscle fibrosis and
increased muscle regeneration and mass, resulting in improving overall life expectancy and locomotion [205]. Additional
studies elucidating the mechanism between autophagy and
muscle homeostasis and regeneration is needed and would
expand our understanding of autophagy and its biological
impact in tissue systems. In cancer biology, laminin α2 also
plays diverse roles in cancer. For example, laminin 211 binds
to integrin α7 to effectively stimulate the proliferation of
acute myeloid leukaemia cells with granulocytic sarcoma via
increased ERK signalling [206]. Separately, LAMA2 expression
inhibits lung adenocarcinoma metastasis, such that destabilizing LAMA2 mRNA through Mex3a binding promotes lung
adenocarcinoma cell migration and invasion [207]. In glioblastoma (GBM), laminin α2 promotes GBM cell growth and selfrenewal and is correlated to negative patient prognoses [208].
Finally, laminin α2 expression is upregulated in the basement
membranes of endothelial cells supplying lung small and
large cell neuroendocrine carcinomas, resulting in metastasis
through an EGF-dependent pathway [209]. These studies
further elucidate the cancer-specific role of laminin α2 in cell
migration and proliferation.
As cellular growth is often linked to heparan sulfatecarrying proteoglycans, it is not surprising that HSPGs
functioning as co-receptors to promote growth factor activity
and positioned within signalling networks could also be
involved in regulating autophagy (figure 3). In Drosophila,
downregulating heparan sulfate biosynthesis increases
autophagy at the neuromuscular junction [210]. Diminishing
heparan sulfate levels globally activates autophagy-dependent
processes, increasing lifespan, reactive oxygen species (ROS)
resistance and decreases build-up of ubiquitin-modified
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The field linking autophagy to ECM has been recently
extended to include heparanase, an endoglucuronidase that
uniquely cleaves cell surface heparan sulfate chains, basement
membranes and ECM proteoglycans [217]. Mechanistically,
heparanase releases a plethora of growth factors, cytokines
and chemokines bound to heparan sulfate chains in the glycocalyx and stromal counterparts, thereby playing a vital role in
creating a permissive environment for cell growth [218–221].
As part of a complex network of remodelling enzymes [222],
heparanase is known to promote myeloma stemness and
tumorigenesis [223] and synergize with chemotherapy to
drive macrophage activation and cancer growth [224].
Furthermore, anti-myeloma chemotherapy evokes secretion
of exosomes enriched in heparanase that remodel the tumour
stroma and contribute to chemoresistance and patient relapse
[225]. Notably, targeting heparanase to the mammary epithelium promotes tumour growth and metastasis [226]. Mice
transplanted with bone marrow-derived from heparanaseoverexpressing transgenic mice show enhanced tumour
aggressiveness and shorter survival times [227]. Moreover,
heparanase enhances autophagy, and this process favours
tumour growth and chemoresistance [228–230]. Clinical trials
testing heparanase inhibitors as an anti-cancer therapy show
early signs of efficacy [231], further underscoring the clinical
importance of this enzyme [218].
An intriguing ECM constituent is the matricellular protein
thrombospondin 1 (Thbs1), one of the first anti-angiogenic
factors to be identified and studied [232]. Thbs1 binds with
high affinity to CD47, a ubiquitously expressed cell surface
receptor which mediates global cardiovascular function and
responses to stress [233]. Notably, CD47 deficiency acts as a
pro-survival factor through activation of the autophagic

7. Conclusion and future perspectives
A growing body of research reveals the impact of autophagy
on ECM function. For example, the realization that autophagy plays a key role in intervertebral disc and cartilage
biology [240] and wound healing [241] provides some hints
for future directions and a prospective translational impact
for therapeutic application. Another intriguing observation
is the link between syndecan 4, a member of the cell surface
HSPGs, and autophagy as it relates to alveolar bone resorption in periodontitis [242]. Yet another recent observation is
the report that progranulin, a growth factor that interacts
with perlecan [172], is a negative regulator of autophagy
[243]. The playing field of proteoglycan research is expanding, given the discovery of novel proteoglycans using mass
spectrometry [244] in Caenorhabditis elegans, and glycoproteomics approaches in both C. elegans and mammalian cells
[245–247]. Intriguingly, some of these novel chondroitin sulfate proteoglycans are canonical prohormones, typically
stored and secreted from granules of endocrine cells [248].
Although ECM-driven processes that drive cancer are
profound [2], the vast majority of cancer research is restricted
to the cancer cell itself. As a result, less focus is placed on
ECM pathology within the tumorigenic milieu. However, in
effort to curtail cancer growth on all fronts, it is equally
important to address the deleterious effects on tumorigenesis
stemming from the ECM as much as it is to address the
metastatic and proliferative changes in the cancer cell.
Importantly, research focused on how a dysfunctional
ECM fundamentally drives disease processes such as desmoplasia, EMT and tumour vascularization is fundamental in
treating cancer from an extracellular front. Within this
realm of ECM-driven pathology in cancer, an emerging
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6. The field is expanding: heparanase and
thrombospondin 1

flux; thus, CD47 blockade could act as a modulator of autophagy and radioprotection [234]. These observations have
been expanded to invasive breast cancer where a combinatorial treatment of anthracyclines and anti-CD47 antibodies
inhibits cancer growth while preventing cardiac toxicity via
autophagy induction [235]. More recent studies have shown
that CD47 mediates autophagy in RAS-expressing cancer
cell lines and triggers tumour growth inhibition [236]. In
agreement with these studies, intact CD47 signalling suppresses autophagy following renal IRI in both native and
transplanted kidneys, in contrast to CD47−/− kidneys which
exhibit a robust increase in autophagic markers [237]. Thus,
targeting CD47 in acute renal injury could ameliorate of
renal function following injury [237]. Finally, it is worth
noting that the anti-angiogenic Thbs1 has been recently
identified as an autophagy activator by triggering the
PERK–eF2α–ATF4 stress axis [238], similar to that evoked
by anti-angiogenic endorepellin in endothelial cells [239].
Specifically, Thbs1, but not Thbs2–4, induces lethal cardiac
atrophy via stress-evoked autophagy and acts as a critical
regulator of cardiomyocyte size in the stressed heart [238].
Obviously, some of these recent reports need to be independently confirmed in different experimental models and
human pathologies by other investigators. Nonetheless, a central theme that is emerging is that disturbances in matrix
constituents and molecules with high affinity for ECM affect
the intracellular process of self-eating, and ultimately the
outcome of cancer and other diseases.

royalsocietypublishing.org/journal/rsob

proteins following ROS exposure [211]. Of interest is the observation that low molecular weight heparin, an over-sulfated
form of heparan sulfate, prevents autophagic induction in activated neutrophils and the formation of neutrophil extracellular
traps [212]. Another glycosaminoglycan, chondroitin sulfate,
binds and activates protein tyrosine phosphatase receptor
sigma (PTPRσ) which, in turn, dephosphorylates cortactin
[213], a PTPRσ-interacting protein identified by proximitylabelling assay [214]. This inhibitory activity occurs at the
autophagosome-lysosome fusion step thereby disrupting
autophagy flux at axonal tips and ultimately leading to
axonal growth inhibition [213]. The sulfation pattern of the glycosaminoglycan chain determines the precise glycan length
that interacts with PTPRσ and defines the fate of axonal regeneration through a complex interaction among PTPRσ, cortactin
and autophagy [215]. These studies are in agreement with the
well-known effect of chondroitinase ABC in promoting axonal
growth and functional recovery after spinal cord injury [216].
Overall, these findings implicate heparan and chondroitin sulfate as effective inhibitors of autophagy. The mechanism by
which these two glycosaminoglycans inhibit autophagy has
yet to be fully elucidated. How these extracellular polysaccharides influence intracellular recycling and degradation and the
receptors and signalling molecules at play is an interesting
question, and its answer would benefit both the glycobiology
and autophagy fields.
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